Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.30 |
| ▸ | IL17A | Q16552 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171252 | 0.90 | CNR2 (0.34) | CNR2CNR1 | |
| SCHEMBL10171246 | 0.90 | CNR2 (0.34) | CNR2CNR1 | |
| SCHEMBL10171256 | 0.87 | — | — | |
| SCHEMBL12746797 | 0.84 | PIK3CD (0.33) | CNR2CNR1PIK3CD | |
| SCHEMBL10171143 | 0.83 | — | — | |
| SCHEMBL10147821 | 0.81 | CNR2 (0.40) | CNR2CNR1PIK3CD | |
| SCHEMBL18638816 | 0.78 | CNR2 (0.39) | CNR2CNR1 | |
| SCHEMBL10146087 | 0.78 | CNR2 (0.39) | CNR2CNR1 | |
| SCHEMBL10171240 | 0.77 | MAPT (0.30) | — | |
| SCHEMBL10171278 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595959-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-11-04 | — | — | EP | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885PIK3CD 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.